Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tyler Brady"'
Autor:
Renata Rozovsky, Michele Bertocci, Satish Iyengar, Richelle S. Stiffler, Genna Bebko, Alexander S. Skeba, Tyler Brady, Haris Aslam, Mary L. Phillips
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract The number of young adults seeking help for emotional distress, subsyndromal-syndromal mood/anxiety symptoms, including those associated with neuroticism, is rising and can be an early manifestation of mood/anxiety disorders. Identification
Externí odkaz:
https://doaj.org/article/b7ee50a24d8549c08369c4cb129cff02
Autor:
Gustavo H. Kijak, Bahar Ahani, Douglas Arbetter, Fernando Chuecos, Vancheswaran Gopalakrishnan, Jagadish Beloor, Tyler Brady, Amy Nguyen, Tiffany L. Roe, Nicolette Schuko, Tianhui Zhang, F. D. Richard Hobbs, Francisco Padilla, Elizabeth J. Kelly, Hugh Montgomery, Katie Streicher
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 12, Pp 2691-2707 (2023)
Abstract Introduction AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evoluti
Externí odkaz:
https://doaj.org/article/81d8ce3337a543ba897387fe3803d1b4
Autor:
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lowe
Externí odkaz:
https://doaj.org/article/c72eec9d7aad4feda1ae2f5d53e8d316
Autor:
Tyler Brady, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L. Roe, Kuishu Ren, Kim Rosenthal, Patrick M. McTamney, Michael E. Abram, Katie Streicher, Elizabeth J. Kelly
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 5 (2022)
ABSTRACT AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acut
Externí odkaz:
https://doaj.org/article/98d4176648a242c59e666ffdfbd7fce6
Autor:
Richard Stebbings, Christopher Jones, Peter Cotton, Gillian Armour, Shaun Maguire, Vicky Skellett, Chi-Man Tang, Joanne Goodman, Tyler Brady, Virginia Takahashi, Andrew Daunt, Jean-Martin Lapointe, Taylor S. Cohen
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Severe COVID-19 can be associated with a prothrombotic state, increasing risk of morbidity and mortality. The SARS-CoV-2 spike glycoprotein is purported to directly promote platelet activation via the S1 subunit and is cleaved from host cells during
Externí odkaz:
https://doaj.org/article/c44929d2e5bd4c7cb0271ac7a867a93e
Autor:
Yingyun Cai, Chengjin Ye, Benson Cheng, Aitor Nogales, Masaharu Iwasaki, Shuiqing Yu, Kurt Cooper, David X. Liu, Randy Hart, Ricky Adams, Tyler Brady, Elena N. Postnikova, Jonathan Kurtz, Marisa St Claire, Jens H. Kuhn, Juan Carlos de la Torre, Luis Martínez-Sobrido
Publikováno v:
mBio, Vol 11, Iss 1 (2020)
ABSTRACT Lassa virus (LASV) is endemic in Western Africa and is estimated to infect hundreds of thousands of individuals annually. A considerable number of these infections result in Lassa fever (LF), which is associated with significant morbidity an
Externí odkaz:
https://doaj.org/article/8cc7b2d7a47643b695aca684103bc6c5
Autor:
Tiffany L. Roe, Tyler Brady, Nicolette Schuko, Amy Nguyen, Jagadish Beloor, Johnathan D. Guest, Anastasia A. Aksyuk, Kevin M. Tuffy, Tianhui Zhang, Katie Streicher, Elizabeth J. Kelly, Gustavo H. Kijak
Publikováno v:
Microbiology Spectrum. 11
MAbs are key therapeutic options for COVID-19 prophylaxis and treatment in immunosuppressed and vulnerable populations. Due to the emergence of SARS-CoV-2 variants, including Omicron, it is vital to ensure that neutralization is maintained for MAb-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca491e12c50bd8a18c3894adb4da28dc
https://doi.org/10.1128/spectrum.00333-23
https://doi.org/10.1128/spectrum.00333-23
Autor:
Deidre Wilkins, Annefleur C Langedijk, Robert Jan Lebbink, Christopher Morehouse, Michael E Abram, Bahar Ahani, Anastasia A Aksyuk, Eugenio Baraldi, Tyler Brady, Albert Tian Chen, Hsin Chi, Eun Hwa Choi, Robert Cohen, Daria M Danilenko, Vancheswaran Gopalakrishnan, Anne Greenough, Terho Heikkinen, Mitsuaki Hosoya, Christian Keller, Elizabeth J Kelly, Leyla Kragten-Tabatabaie, Federico Martinón-Torres, Abiel Homero Mascareñas de Los Santos, Marta C Nunes, María Angélica Palomino, Jesse Papenburg, Jeffrey M Pernica, Peter Richmond, Renato T Stein, Kevin M Tuffy, Charl Verwey, Mark T Esser, David E Tabor, Louis J Bont, Pascale Clement, Atul Gupta, Koichi Hashimoto, Kseniya Komissarova, Matt Laubscher, Magali Lumertz, Elena Priante, Irene Rivero-Calle, Ushma Wadia, Ki Wook Yun
Publikováno v:
The Lancet Infectious Diseases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b9df76477908bede262936e17c70dd
https://doi.org/10.1016/s1473-3099(23)00062-2
https://doi.org/10.1016/s1473-3099(23)00062-2
Autor:
Kevin M Tuffy, Michael E Abram, Tiffany L Roe, Bahar Ahani, Tyler Brady, Nicolette Schuko, Lori Clarke, Carolina Caceres, Tara Kenny, Virginia Takahashi, Tianhui Zhang, David E Tabor, Gustavo H Kijak, Elizabeth J Kelly, Katie Streicher
Publikováno v:
Open Forum Infectious Diseases. 9
Background AZD7442 is a combination of extended–half-life SARS-CoV-2–neutralizing monoclonal antibodies (tixagevimab/cilgavimab) that bind to distinct epitopes on the SARS-CoV-2 spike protein. In the PROVENT study, a single 300 mg intramuscular d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f00ad5ab5f006dfffc94566f1d35d046
https://doi.org/10.1093/ofid/ofac492.949
https://doi.org/10.1093/ofid/ofac492.949
Autor:
Michael E Abram, Bahar Ahani, David E Tabor, Fiona Fernandes, Deidre Wilkins, Anastasia A Aksyuk, Kevin M Tuffy, Hong Ji, Christine Blaze, Tyler Brady, Pamela Griffin, Amanda Leach, Tonya L Villafana, Mark T Esser
Publikováno v:
Open Forum Infectious Diseases. 9
Background Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection (LRTI) and hospitalization in infants. In two global pivotal placebo-controlled studies, nirsevimab, a monoclonal antibody to the RSV prefusion (F) p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93db9da2cebce7f4aa7876bbf02658aa
https://doi.org/10.1093/ofid/ofac492.019
https://doi.org/10.1093/ofid/ofac492.019